Summary: Maraviroc is the first CCR5 coreceptor antagonist to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of CCR5-tropic human immunodeficiency virus ...

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

Although more than 350 non-olfactory G-protein coupled receptors (GPCRs) are present in the human genome, only 135 are targeted by currently approved drugs. Beacon Discovery believes there are ...